Evidence map›Paper›PMID 42284534›Full record

Observational studyNeurology2026

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Alexandra Scharf, Jeffrey A Cohen, Ruth Ann Marrie, Aaron E Miller, Emmanuelle Waubant, Meghan Kilbane, Elaina Luskin, Christina J Azevedo, Meredith Dever, Enrique Alvarez and 28 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Alexandra ScharfMellen Center for MS Treatment and Research, Cleveland Clinic, OH.ORCID 0009-0009-3734-7132
Jeffrey A CohenMellen Center for MS Treatment and Research, Cleveland Clinic, OH.ORCID 0000-0001-9245-9772
Ruth Ann MarrieDepartment of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Canada.ORCID 0000-0002-1855-5595
Aaron E MillerCorinne Goldsmith Dickinson Center for MS, Mount Sinai, New York, NY.ORCID 0000-0001-8324-7356
Emmanuelle WaubantUCSF MS and Neuroinflammation Center, University of California San Francisco.ORCID 0000-0001-5188-0157
Meghan KilbaneMellen Center for MS Treatment and Research, Cleveland Clinic, OH.
Elaina LuskinDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA.
Christina J AzevedoDepartment of Neurology, University of Southern California, Los Angeles.ORCID 0000-0002-8622-1845
Meredith DeverMellen Center for MS Treatment and Research, Cleveland Clinic, OH.
Enrique AlvarezUCHealth Neurosciences Center - Anschutz Medical Campus, University of Colorado, Aurora.ORCID 0000-0001-5854-9643
Peter A CalabresiDepartment of Neurology, Johns Hopkins University, Baltimore, MD.ORCID 0000-0002-7776-6472
Salim ChahinDepartment of Neurology, Barnes-Jewish Hospital, St. Louis, MO.ORCID 0000-0002-4115-4300
Leorah FreemanDepartment of Neurology, Dell Medical School, University of Texas at Austin.ORCID 0000-0002-5696-1797
Kunio NakamuraDepartment of Biomedical Engineering, Cleveland Clinic, OH.ORCID 0000-0002-7833-8138
Erin E LongbrakeYale University, New Haven, CT.ORCID 0000-0002-1179-3937
Ellen M MowryDepartment of Neurology, Johns Hopkins University, Baltimore, MD.ORCID 0000-0003-0623-5188
Jiwon OhDivision of Neurology, St. Michael's Hospital, Toronto, Canada.ORCID 0000-0001-5519-6088
Paulo R RodriguesQMENTA, Boston, MA.ORCID 0000-0002-2102-1746
Marc RamosQMENTA, Boston, MA.ORCID 0009-0006-6232-6673
Elias S SotirchosDepartment of Neurology, Johns Hopkins University, Baltimore, MD.ORCID 0000-0002-8812-1637
Gary R CutterUAB School of Public Health, Birmingham, AL.ORCID 0000-0002-8455-980X
Marwa KaiseyDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA.
Moein AminMellen Center for MS Treatment and Research, Cleveland Clinic, OH.ORCID 0000-0002-9587-0644
Karlo ToljanMellen Center for MS Treatment and Research, Cleveland Clinic, OH.ORCID 0000-0002-3189-9659
Nicholas IllenbergerDepartment of Population Health, NYU Langone Health, New York, NY.ORCID 0000-0003-4967-0390
Michel BilelloDepartment of Radiology, University of Pennsylvania, Philadelphia.ORCID 0000-0001-6313-5437
Jonathan LeeImaging Institute, Cleveland Clinic, OH.ORCID 0000-0002-5955-5145
Marcel MayaDepartment of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8236-7671
Emmanuel C ObusezImaging Institute, Cleveland Clinic, OH.
Matthew K SchindlerDepartment of Neurology, University of Pennsylvania, Philadelphia.ORCID 0000-0003-0157-5669
Suradech SuthiphosuwanDepartment of Medical Imaging, St. Michael's Hospital, Toronto, Canada.ORCID 0000-0002-8171-0164
Adam UlanoDepartment of Radiology, Larner College of Medicine at the University of Vermont, Burlington.ORCID 0000-0003-0858-1834
Russell T ShinoharaPenn Statistics in Imaging and Visualization Center, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia.ORCID 0000-0001-8627-8203
Daniel S ReichTranslational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD; and.ORCID 0000-0002-2628-4334
Andrew J SolomonDepartment of Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington.ORCID 0000-0003-1602-1554
Nancy L SicotteDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-5131-3352
Pascal SatiDepartment of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-6763-0125
Daniel OntanedaMellen Center for MS Treatment and Research, Cleveland Clinic, OH.ORCID 0000-0002-2838-9148

Funding

Central Vein Sign: A Diagnostic Biomarker in Multiple SclerosisU01NS116776 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI ONTANEDA, DANIEL, SATI, PASCAL · 2020 to 2024
$7.1M
NINDS NIH HHS U01 NS116776
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe 2024 McDonald criteria allow diagnosis of multiple sclerosis (MS) in individuals presenting with symptoms not specific for MS or incidental imaging findings suggestive of demyelination when supported by biomarker evidence, reflecting a shift toward diagnostic definitions increasingly grounded in biological mechanisms of disease. The diagnostic yield of these criteria in such populations has not been evaluated in multicenter cohorts. We aimed to determine the proportion of individuals with nonspecific or incidental imaging presentations who meet the 2024 McDonald criteria and describe the contribution of central vein sign and CSF oligoclonal bands (OCBs) to diagnostic classification.

methodsThis cross-sectional post hoc analysis used data from the Central Vein Sign in Multiple Sclerosis study, a multicenter observational cohort. Adults aged 18-65 years referred for diagnostic evaluation of possible MS were adjudicated by an expert panel. This analysis focused on participants with symptoms not specific for MS or incidental imaging findings suggestive of demyelination. Dissemination in space (DIS) and dissemination in time (DIT) were assessed using 2017 MRI criteria. Fulfillment of the 2024 McDonald criteria at baseline-the primary outcome-was determined using the Select-6 CVS and CSF OCBs. Select-6 assessment was available for all participants, whereas OCB data were available for a subset based on prior clinical evaluation.

resultsOf 420 participants enrolled, 191 (45%) presented with either nonspecific symptoms (n = 166) or incidental imaging findings (n = 25). The mean age was 42 years, and 78% were female. Thirty-six (19%) met the 2024 McDonald criteria at baseline, including 28 (17%) in the nonspecific symptom cohort and 8 (32%) in the incidental imaging cohort. Among 51 participants meeting 2017 DIS, 22 (43%) were Select-6 positive, 17 (33%) had positive OCBs, and 4 (8%) met 2017 DIT. Nonspecific sensory symptoms, visual disturbances, and subacute cognitive decline were most associated with a diagnosis of MS. DISCUSSION: Application of the 2024 McDonald criteria identified nearly one-fifth of individuals without typical presentations as meeting diagnostic criteria for MS at baseline. Biomarker incorporation-particularly the CVS-accounted for a substantial proportion of diagnostic yield. Interpretation is limited by availability of CSF data and absence of longitudinal follow-up.

Indexed as

Multiple SclerosisAdolescentAdultAgedBiomarkersCohort StudiesCross-Sectional StudiesDemyelinating DiseasesFemaleHumansIncidental FindingsMagnetic Resonance ImagingMaleMiddle AgedOligoclonal BandsYoung AdultBiomarkersOligoclonal Bands

Identifiers

PMID42284534
PMCPMC13267864

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.